Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

200.54
-2.8150-1.38%
Volume:257.40K
Turnover:52.22M
Market Cap:42.98B
PE:-22.48
High:206.36
Open:204.98
Low:200.41
Close:203.35
52wk High:224.31
52wk Low:42.18
Shares:214.34M
Float Shares:185.00M
Volume Ratio:0.92
T/O Rate:0.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.49
PE(LYR):-33.70

Loading ...

Movement Alert|Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Core Drug NDA Formally Accepted by FDA

Market Focus
·
Jul 23

Revolution Medicines Inc : Wedbush Raises Target Price to $192.1 from $181

THOMSON REUTERS
·
Jul 23

Wedbush Raises Price Target on Revolution Medicines to $192.10 From $181, Keeps Outperform Rating

MT Newswires Live
·
Jul 23

Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price Target

TIPRANKS
·
Jul 23

Revolution Medicines receives FDA review acceptance for daraxonrasib

TIPRANKS
·
Jul 23

Revolution Medicines Says FDA Accepts Daraxonrasib NDA for Previously Treated Metastatic Pancreatic Cancer

Reuters
·
Jul 23

Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Jul 23

Revolution Medicines is Maintained at Buy by Needham

Dow Jones
·
Jul 20

Movement Alert|Revolution Medicines Falls 5.11% in Pre-Market Trading, Trading at $172.36

Market Focus
·
Jul 17

Revolution Medicines Inc : JP Morgan Raises Target Price to $205 from $200

THOMSON REUTERS
·
Jul 16

Analysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD)

TIPRANKS
·
Jul 11

Analysts Offer Insights on Healthcare Companies: Simulations Plus (SLP), Alnylam Pharma (ALNY) and Revolution Medicines (RVMD)

TIPRANKS
·
Jul 10

Revolution Medicines is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 09

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Satellos Bioscience (MSLE) and Intuitive Surgical (ISRG)

TIPRANKS
·
Jul 09

Revolution Medicines price target raised to $235 from $205 at Guggenheim

TIPRANKS
·
Jul 09

Revolution Medicines (RVMD) Wins Faster Reviews, Is The Valuation Already Too Rich?

Simply Wall St.
·
Jul 09

RASolute 305: RVMD Targets KRAS G12D Pancreatic Cancer in a Pivotal Phase 3 Trial

TIPRANKS
·
Jul 09

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

THOMSON REUTERS
·
Jul 07

Revolution Medicines Rises as EU Regulator Starts Phased Review of Cancer Drug

Reuters
·
Jul 07

EMA Fast Tracks Review of Medicine for Metastatic Pancreatic Cancer

Reuters
·
Jul 07